Eradication of Aspiculuris tetraptera in various immunodeficient mouse models using ivermectin: a case report

TL;DR

This case report shows that ivermectin injections and environmental spraying successfully eradicated a pinworm infection in immunodeficient mice.

Contribution

A practical treatment protocol using ivermectin for eradicating Aspiculuris tetraptera in immunodeficient mouse models is proposed.

Findings

Subcutaneous ivermectin injections and environmental spray application eliminated A. tetraptera infestation in immunodeficient mice.

Post-treatment testing showed no presence of A. tetraptera eggs or adult worms in the mouse colonies.

The treatment protocol did not result in any mortality among the mice.

Abstract

Despite advancements in laboratory animal facility management, pinworm infections remain a persistent issue in immunodeficient mouse colonies. Rapid diagnosis and treatment are crucial to mitigating potential scientific and economic consequences. Effective control requires both the administration of anthelmintic agents and rigorous environmental decontamination. However, the safety and efficacy of these treatments in genetically modified mouse models remains uncertain.

Aspiculuris
tetraptera infestation was identified in multiple immunodeficient mouse models housed in a laboratory facility. Diagnosis was confirmed through fecal flotation for egg detection and necropsy for adult worm examination in the large intestines. Mice received three subcutaneous ivermectin injections at two-week intervals, coupled with environmental decontamination using ivermectin spray for four consecutive weeks. Following treatment, all colonies tested negative for A. tetraptera without any mortality.

A combination of subcutaneous ivermectin injection and environmental spray application effectively eradicated A. tetraptera infestation in immunodeficient mouse colonies. The treatment protocol led to the complete elimination of eggs and adult worms, offering a practical strategy for managing pinworm infections in genetically modified mouse models. Limitations include the small sample size, and the lack of a comprehensive evaluation of physiological and metabolic safety in immunodeficient mice. Further validation will be required to confirm the broader applicability of this approach.

Figures